Keywords: glaxosmithkline, buy, uk, mabs, firm, domantis, l230
GlaxoSmithKline to buy UK MAbs firm Domantis for L230 million, in cash
Article | 18 December 2006
Drugs giant GlaxoSmithKline has entered into an agreement to acquire fellow UK-headquartered Domantis, a privately-held developer of next-generation antibody therapies, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
